Rucaparib or Physician's Choice in Metastatic Prostate Cancer

Por um escritor misterioso

Last updated 19 março 2025

Rucaparib or Physician's Choice in Metastatic Prostate Cancer

The Latest Developments on PARP Inhibitors for Prostate Cancer Treatment

Prevalence and clinical impact of tumor BRCA1 and BRCA2 mutations in patients presenting with localized or metastatic hormone-sensitive prostate cancer

Rucaparib or Physician's Choice in Metastatic Prostate Cancer

TRITON-3 Validates Rucaparib Monotherapy After a Prior ARPI but Before Chemotherapy in BRCA-Mutated mCRPC

Rucaparib extends PFS in advanced prostate cancer

Novel therapies are changing treatment paradigms in metastatic prostate cancer, Journal of Hematology & Oncology

Both Olaparib and Rucaparib Demonstrate Efficacy for Metastatic Castration-Resistant Prostate Cancer

Frontiers Comparative efficacy of olaparib in combination with or without novel antiandrogens for treating metastatic castration-resistant prostate cancer

PDF) A Case Study of Clinical Response to Rucaparib in a Patient with Metastatic Castration-Resistant Prostate Cancer and a RAD51B Alteration

Recomendado para você